Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 5
1979 1
1980 1
1981 1
1982 2
1983 2
1984 9
1985 6
1986 6
1987 5
1988 3
1989 3
1990 4
1991 6
1992 5
1993 8
1994 3
1995 4
1996 2
1997 1
1998 3
1999 9
2000 10
2001 5
2002 21
2003 5
2004 13
2005 13
2006 15
2007 10
2008 6
2009 8
2010 3
2011 5
2012 5
2013 4
2014 5
2015 8
2016 3
2017 4
2018 7
2019 3
2020 2
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Results by year

Filters applied: . Clear all
Page 1
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. von der Maase H, et al. J Clin Oncol. 2000 Sep;18(17):3068-77. doi: 10.1200/JCO.2000.18.17.3068. J Clin Oncol. 2000. PMID: 11001674 Corrected and republished. Clinical Trial.
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. von der Maase H, et al. J Clin Oncol. 2023 Aug 10;41(23):3881-3890. doi: 10.1200/JCO.22.02763. J Clin Oncol. 2023. PMID: 37549482
Radiotherapy in bladder cancer.
Sengeløv L, von der Maase H. Sengeløv L, et al. Among authors: von der maase h. Radiother Oncol. 1999 Jul;52(1):1-14. doi: 10.1016/s0167-8140(99)00090-0. Radiother Oncol. 1999. PMID: 10577680 Review.
[Immunotherapy of cancer].
Andersen MH, Schmidt H, Gehl J, von der Maase H, Straten P. Andersen MH, et al. Among authors: von der maase h. Ugeskr Laeger. 2002 Jun 3;164(23):3008-16. Ugeskr Laeger. 2002. PMID: 12082849 Review. Danish.
[Oncologic treatment].
von der Maase H. von der Maase H. Ugeskr Laeger. 2002 Jun 3;164(23):2999. Ugeskr Laeger. 2002. PMID: 12082846 Danish. No abstract available.
Gemcitabine in advanced bladder cancer.
von der Maase H. von der Maase H. Semin Oncol. 2001 Apr;28(2 Suppl 7):11-4. doi: 10.1053/sonc.2001.24369. Semin Oncol. 2001. PMID: 11372046 Review.
230 results